Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 01/18 04:59:40 pm
250.5 DKK   +0.24%
01/16 LAWSUIT FOR INV : Nvo)
01/16 NOVO NORDISK A/ : - Share repurchase programme
01/13 Rosen Law Firm Announces Filing of Securities Class Action Lawsui..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on NOVO NORDISK A/S
01/16 LAWSUIT FOR INVESTORS WHO LOST MONEY : Nvo)
01/16 NOVO NORDISK A/S : - Share repurchase programme
01/13 Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against No..
01/12 NOVO NORDISK A/S : An Application for the Trademark "SOLVE" Has Been Filed by No..
01/12 NOVO NORDISK A/S : Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Clas..
01/12 REPORTS ON GLUCAGON THERAPY FROM NOV : Chemical...
01/12 NOVO NORDISK A/S : Researchers Submit Patent Application, "Mating Factor Alpha P..
01/12 INVESTIGATORS AT NOVO NORDISK TARGET : ...
01/11 NOVO NORDISK A/S : Fiasp (fast-acting insulin aspart) approved in Europe
01/11 NOVO NORDISK A/S : Fiasp (fast-acting insulin aspart) approved in Europe
01/10 NOVO NORDISK A/S : Fiasp® (fast-acting insulin aspart) approved in Europe
01/10 NOVO NORDISK A/S : Former Steeler Kendall Simmons' NFL career helped him manage ..
01/09 NOVO NORDISK A/S : and Glooko partner to develop digital health solutions for pe..
01/09 NOVO NORDISK A/S : - Share repurchase programme
01/09 NOVO NORDISK A/S : Glooko Partner to Develop Digital Health Solutions for People..
01/06 NOVOZYMES A/S : Patent Issued for Subtilase Variants (USPTO 9528100)
01/03 ROYAL BANK OF CANADA : The Brookmont Capital Management Reached $1,683,000 Posit..
01/02 NOVO NORDISK A/S : - Status regarding Novo Nordisk's holding of its own shares (..
2016 NOVO NORDISK A/S : Patent Issued for Injection Device Comprising an Optical Sens..
2016 NOVO NORDISK A/S : Receives FDA Approval of Tresiba® insulin degludec injection ..
2016 FLUOR NEW : to Design and Build $2 Billion Diabetes API Manufacturing Facility f..
2016 NOVO NORDISK A/S : LYFEBULB-NOVO NORDISK Gaur named finalist for award
2016 SANOFI SA (NYSE : SNY) Files Suit Against Novo Nordisk A/S (ADR) (NYSE:NVO) Over..
2016 NOVO NORDISK A/S : aktietilbagekøbsprogram
2016 NOVO NORDISK A/S : Fluor to Build Huge NC Pharma Plant for Novo Nordisk
2016 NOVO NORDISK A/S : - Share repurchase programme
2016 FLUOR NEW : Awarded Contract to Build $2B Diabetes API Manufacturing Facility fo..
2016DJRoche Says Hemophilia Drug Reduces Bleeding in Late-Stage Trial
2016 FLUOR NEW : to build US$2 billion pharmaceutical facility
2016 Roche's emicizumab haemophilia drug succeeds in trial
2016 NOVO NORDISK A/S : "Dose Titration Aid" in Patent Application Approval Process (..
2016 NOVO NORDISK A/S : New Data from Novo Nordisk Illuminate Findings in Corpus Lute..
2016 NOVO NORDISK A/S : Fluor lands $1.2bn contract for US pharmaceutical complex
2016 NOVO NORDISK A/S : NCDOT ramping up construction for Novo Nordisk expansion
2016 NOVO NORDISK A/S : - Share repurchase programme
2016 NOVO NORDISK A/S : recognized for diversity and inclusion
2016 EMISPHERE TECHNOLOGIES, INC. (OTCMKT : EMIS) Files An 8-K Entry into a Material ..
2016 NOVO NORDISK A/S : - Share repurchase programme
2016 EMISPHERE TECHNOLOGIES, INC. (NASDAQ : EMIS) Files An 8-K Entry into a Material ..
2016 EMISPHERE TECHNOLOGIES, INC. (LON : EMIS) Files An 8-K Entry into a Material Def..
2016 EMISPHERE TECHNOLOGIES : Restructures Debt Agreements, Providing Greater Stabili..
2016 NOVO NORDISK A/S : Smithfield chamber, residents oppose jail
2016 NOVO NORDISK A/S : Patient Entrepreneur Brianna Wolin of Find Your Ditto Selecte..
2016DJCorrection to Novo Nordisk Pledges to Limit Price Increases in US for Its Dru..
2016DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
2016DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
2016 NOVO NORDISK A/S : NovoSeven resolved 96.5% of bleeds in haemophilia A or B suff..
2016 NOVO NORDISK A/S : NovoSeven resolved 96.5% of bleeds when initiated within one ..
2016 NOVO NORDISK A/S : Xultophy demonstrates similar glucose control with reduced ri..
2016 NOVO NORDISK A/S : files for regulatory approval of once-weekly semaglutide in t..
2016 NOVO NORDISK A/S : - Share repurchase programme
2016 NOVO NORDISK A/S : NovoSeven® resolved 96.5% of bleeds when initiated within one..
2016 NOVO NORDISK A/S : Xultophy® demonstrates similar glucose control with reduced r..
2016 NOVO NORDISK A/S : Xultophy Demonstrates Similar Glucose Control with Reduced Ri..
2016 NOVO NORDISK A/S : Patent Issued for Method and System for Self-Management of a ..
2016 NOVO NORDISK A/S : Findings from Novo Nordisk Broaden Understanding of Pharmacol..
2016 NOVO NORDISK A/S : Study Results from Novo Nordisk in the Area of Quality of Lif..
2016 NOVO NORDISK A/S : Receives FDA Approval for Xultophy® 100/3.6 insulin degludec ..
2016DJNOVO NORDISK A/S : New Insulin Reduces Risk of Low Blood Sugar, Study Shows
2016DJNOVO NORDISK A/S : New Insulin Reduces Risk of Low Blood Sugar, Study Shows
2016DJNOVO NORDISK A/S : New Insulin Reduces Risk of Low Blood Sugar, Study Shows
2016 NOVO NORDISK A/S : reports Tresiba insulin achieves target in study
2016 NOVO NORDISK A/S : Tresiba® demonstrates a safe cardiovascular profile and reduc..
2016 NOVO NORDISK A/S : - Share repurchase programme
2016DJDrugmakers Find Competition Doesn't Keep a Lid on Prices
2016 NOVO NORDISK A/S : Clayton, county launch sewer authority
2016 US FDA APPROVES SANOFI SA (NYSE : SNY) Soliqua 100/33, Novo Nordisk A/S (NYSE:NV..
2016 NOVO NORDISK A/S : Findings from Novo Nordisk Provides New Data about Saccharomy..
2016 REPORTS ON OBESITY FROM NOVO NORDISK : A Population Pharmacokinetic Analysis)
2016 NOVO NORDISK A/S : receives US FDA approval for Xultophy 100/3.6
2016 NOVO NORDISK A/S : receives US FDA approval for Xultophy 100/3.6
2016 NOVO NORDISK A/S : receives US FDA approval for Xultophy® 100/3.6
2016 NOVO NORDISK A/S : - Share repurchase programme
2016 NOVO NORDISK A/S : Modern diabetes centre opened in Nakuru
2016 Indian pharma companies missing on access to medicine index
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( DKK)
Sales 2016 111 793 M
EBIT 2016 48 740 M
Net income 2016 38 058 M
Finance 2016 13 818 M
Yield 2016 2,85%
P/E ratio 2016 16,64
P/E ratio 2017 15,72
EV / Sales 2016 4,38x
EV / Sales 2017 4,18x
Capitalization 502 940 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 281  DKK
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-0.98%72 320
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results